Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155763 | 1.00 | GRM5 (0.33) | GRM5PI4KBSYKPTGDR2MDM2 | |
| SCHEMBL4158161 | 0.93 | KDM4E (0.35) | GRM5PI4KBSYKUSP30 | |
| SCHEMBL4158162 | 0.93 | KDM4E (0.35) | GRM5PI4KBSYKUSP30 | |
| SCHEMBL4143133 | 0.91 | NR1I2 (0.31) | USP30 | |
| SCHEMBL4143135 | 0.91 | NR1I2 (0.31) | USP30 | |
| SCHEMBL13852281 | 0.89 | GRM5 (0.32) | GRM5PI4KBSYK | |
| SCHEMBL4138722 | 0.88 | APOBEC3A (0.33) | PI4KBSYKUSP30 | |
| SCHEMBL4138718 | 0.88 | APOBEC3A (0.33) | PI4KBSYKUSP30 | |
| SCHEMBL13852136 | 0.83 | KDM4E (0.36) | SYKUSP30 | |
| SCHEMBL4147318 | 0.83 | KDM4E (0.36) | SYKUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | claimed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | GRM5 3788/4885PI4KB 2486/4885SYK 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.